Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

154.16 14.42 −8.55%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a

Guardant Health, Inc. (GH) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Guardant Health, Inc. (GH) trades at a P/S ratio of 16.2×. Over the past ten years it has ranged from 3.2× (April 2024) to 70.8× (June 2019); the current reading is higher than 56% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 13.0× 157.00%
FY2024 5.1× (3.61%)
FY2023 5.3× (14.22%)
FY2022 6.1× (77.37%)
FY2021 27.1× (38.12%)
FY2020 43.8× 32.72%
FY2019 33.0× 161.90%
FY2018 12.6× 114.42%
FY2017 5.9× 0.00%
FY2016 5.9× —

Quarterly newest first

Period P/S ratio Change
Sep 2026 18.7× 11.27%
Jun 2026 16.8× 50.10%
Mar 2026 11.2× (13.92%)
Dec 2025 13.0× 50.93%
32 more quarters

Against its own ten years

Low 3.2× High 70.8×
Ten-year median 13.5×
Current reading's percentile 56

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on GH